Ignite Creation Date:
2025-12-25 @ 3:07 AM
Ignite Modification Date:
2026-03-15 @ 3:25 AM
Study NCT ID:
NCT04948333
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-23
First Post:
2021-06-28
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CABL001A2302
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None